The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: US debt uncertainty persists, Footsie finishes under

Mon, 25th Jul 2011 16:42

The Footsie trimmed earlier gains as markets in the US recovered after a weak start. Despite falling as low as 5,893 on Monday, London's blue chip index finished firmly above the 5,900 mark, as giants BP, ARM, BG and GlaxoSmithKline rose ahead of their interim results due tomorrow. While stocks on Wall Street took a hit after the opening bell, the retreat wasn't as bad as many had expected, even though the nation is only eight days from a possible default. Investors continued "to call Washington's bluff" in regards to the debt ceiling talks, according to CNNMoney, which suggested that investors do not believe that government officials will allow the US to default on its debt.Meanwhile, the euro crisis raged on after ratings agency Moody's downgraded Greece's sovereign debt rating by three notches from Caa1 to Ca, a mere two stations above a rating that would signify a default. Investors are concerned that Spain and even Italy could be next in the firing line. Back in London on the FTSE 100, silver producer Fresnillo finished as a high riser on the back of a rising silver price, which increased by 0.74% to $40.42 at 16:44. Gold prices edged upwards also, as nervousness over the US debt talks boosted the safe-haven appeal of precious metals.The banks were among the worst performers as volatility in the sector continues amidst the ongoing euro crisis. Banking shares rallied on Thursday after European leaders agreed a new aid package for Greece and an overhaul of the Eurozone sovereign rescue fund. However, Barclays, RBS and Lloyds were all lower today as a result of concern about the future of the single currency. Insurers Aviva, Resolution, Admiral and Standard Life were also among the heavy fallers.Sector peers Melrose and Charter International were rising after Melrose said today that it is thinking over whether or not to up its bid for Charter after the target dismissed its first two offers. "Melrose is willing to consider increasing its proposal to reflect any information which demonstrates that it has materially undervalued Charter and justifies such an increase," the firm said. Dixons Retail was a heavy faller on the FTSE 250 after UBS downgraded the electricals retailer from "neutral" to "sell", saying that trading is "set to remain tougher for longer". The Swiss broker thinks that Dixons, which owns PC World and Currys, is likely to report a weak first quarter "given the tough World Cup comparative [of last year] but we expect [the second half] to remain tough". Leading the risers was pizza delivery group Domino's Pizza, after it posted a sharp rise in first-half profits in the first half of the year despite the tough economic climate. BCFTSE 100 - RisersFresnillo (FRES) 1,729.00p +2.86%Weir Group (WEIR) 2,210.00p +2.55%United Utilities Group (UU.) 598.00p +1.70%GlaxoSmithKline (GSK) 1,363.50p +1.68%Burberry Group (BRBY) 1,600.00p +1.39%Capital Shopping Centres Group (CSCG) 386.10p +1.39%Reckitt Benckiser Group (RB.) 3,526.00p +1.38%GKN (GKN) 238.20p +1.15%BG Group (BG.) 1,425.00p +1.10%Hammerson (HMSO) 477.10p +1.10%FTSE 100 - FallersBarclays (BARC) 228.95p -4.44%Lloyds Banking Group (LLOY) 45.10p -4.30%Aviva (AV.) 412.60p -3.01%Resolution Ltd. (RSL) 281.90p -2.32%Hargreaves Lansdown (HL.) 596.00p -2.05%Admiral Group (ADM) 1,562.00p -2.01%Autonomy Corporation (AU.) 1,662.00p -1.71%Cairn Energy (CNE) 386.80p -1.58%Royal Bank of Scotland Group (RBS) 36.28p -1.57%Vodafone Group (VOD) 162.00p -1.55%
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.